Contact Information
1701 Jackson Street#102
San Francisco, CA 94109
Phone: (917) 653-0470
Contact: William J. Garner, MD
Email: bill@inverseon.com
Website: http://www.inverseon.com
Inverseon Inc. Company Profile
Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.News from Inverseon Inc.:
INV102 Asthma Product Discussed at the European Respiratory Society
SAN FRANCISCO, Sept. 22, 2009 — A symposium was held last week at the European Respiratory Society’s annual meeting in Vienna, Austria entitled “Beta-blockers may now be beneficial in asthma and COPD.”
“It is remarkable how far Inverseon’s asthma program has a…
Inverseon’s Founder and SAB Member Published in PNAS
SAN FRANCISCO, Feb. 19, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the publication in the February 17, 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) entitled, “Beta2-adrenoceptor signaling is required for the development of an asthma phen…
Inverseon’s Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
SAN FRANCISCO, Jan. 14, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the receipt of a notice of allowance from the United States Patent Office covering its oral product INV102 for asthma. Additionally, a comment highlighting Inverseon’s clinical asthma study was publ…
Drug Reduces Airway Mucus in Preclinical Asthma Model
SAN FRANCISCO, Feb. 19, 2008 — Inverseon, Inc. (http://www.inverseon.com) announces the publication of a rapid communication of groundbreaking research led by Professor Richard Bond of the University of Houston, Inverseon’s Scientific Founder. In the March article by Nguyen, et. al…
Inverseon Announces Positive Phase IIa Asthma Study
SAN FRANCISCO, Jan. 29, 2008 — Inverseon, Inc. (http://www.inverseon.com) announces the publication of a positive phase IIa clinical trial in asthma.
In the article by Hanania et al., in Pulmonary Pharmacology & Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety an…